Q4 2023
Released May 22, 2023, before the open
10-K filed May 22, 2023, 52 days after period end · 0001764013-23-000065
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$59.43M-$59.43M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$55,793,000N/M
Free Cash Flowderived-$55,819,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2018 |
|---|---|---|---|
| Net Income | -$59.43M | -$47.17M | -$450.00 |
| EPS Diluted | — | — | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR